IL257840B2 - T cell receptors recognizing hla-cw8 restricted mutated kras - Google Patents

T cell receptors recognizing hla-cw8 restricted mutated kras

Info

Publication number
IL257840B2
IL257840B2 IL257840A IL25784018A IL257840B2 IL 257840 B2 IL257840 B2 IL 257840B2 IL 257840 A IL257840 A IL 257840A IL 25784018 A IL25784018 A IL 25784018A IL 257840 B2 IL257840 B2 IL 257840B2
Authority
IL
Israel
Prior art keywords
seq
amino acid
acid sequence
val
ile
Prior art date
Application number
IL257840A
Other languages
English (en)
Hebrew (he)
Other versions
IL257840A (en
IL257840B1 (en
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of IL257840A publication Critical patent/IL257840A/en
Publication of IL257840B1 publication Critical patent/IL257840B1/en
Publication of IL257840B2 publication Critical patent/IL257840B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
IL257840A 2015-09-15 2016-09-09 T cell receptors recognizing hla-cw8 restricted mutated kras IL257840B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562218688P 2015-09-15 2015-09-15
PCT/US2016/050875 WO2017048593A1 (en) 2015-09-15 2016-09-09 T cell receptors recognizing hla-cw8 restricted mutated kras

Publications (3)

Publication Number Publication Date
IL257840A IL257840A (en) 2018-04-30
IL257840B1 IL257840B1 (en) 2023-06-01
IL257840B2 true IL257840B2 (en) 2023-10-01

Family

ID=56985686

Family Applications (1)

Application Number Title Priority Date Filing Date
IL257840A IL257840B2 (en) 2015-09-15 2016-09-09 T cell receptors recognizing hla-cw8 restricted mutated kras

Country Status (13)

Country Link
US (3) US10556940B2 (cg-RX-API-DMAC7.html)
EP (2) EP3901169A1 (cg-RX-API-DMAC7.html)
JP (2) JP7185524B2 (cg-RX-API-DMAC7.html)
KR (2) KR102841067B1 (cg-RX-API-DMAC7.html)
CN (2) CN108350059B (cg-RX-API-DMAC7.html)
AU (3) AU2016323017B2 (cg-RX-API-DMAC7.html)
DK (1) DK3350213T3 (cg-RX-API-DMAC7.html)
ES (1) ES2879287T3 (cg-RX-API-DMAC7.html)
IL (1) IL257840B2 (cg-RX-API-DMAC7.html)
MX (1) MX2018003062A (cg-RX-API-DMAC7.html)
SA (1) SA518391109B1 (cg-RX-API-DMAC7.html)
SG (1) SG10201913868XA (cg-RX-API-DMAC7.html)
WO (1) WO2017048593A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2592821B (en) 2015-07-31 2022-01-12 Univ Minnesota Modified cells and methods of therapy
IL301894B2 (en) * 2016-08-02 2025-02-01 Us Health Anti-KRAS-G20 T-cell receptors
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
EP3602053B1 (en) * 2017-03-31 2023-06-28 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of isolating neoantigen-specific t cell receptor sequences
AU2018269370B2 (en) 2017-05-16 2025-06-05 The Johns Hopkins University Manabodies and methods of using
CN111511375A (zh) 2017-06-30 2020-08-07 因提玛生物科学公司 用于基因治疗的腺相关病毒载体
BR112020005469A2 (pt) * 2017-09-20 2020-09-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services receptores de células t restritivas a hla classe ii contra ras mutado
CA3077595A1 (en) 2017-10-05 2019-04-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for diagnosing, monitoring and treating neurological diseases and disorders
CR20200287A (es) * 2017-12-04 2020-11-11 Us Health Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado
JP7534962B2 (ja) 2018-06-19 2024-08-15 ビオンテック ユーエス インコーポレイテッド ネオ抗原およびその使用
CN112888707B (zh) 2018-08-16 2025-04-25 百欧恩泰美国公司 T细胞受体构建体及其用途
CN120607607A (zh) * 2019-01-22 2025-09-09 美国卫生和人力服务部 针对含有g12r突变的ras的hla第ii类限制性t细胞受体
KR20210130189A (ko) 2019-02-20 2021-10-29 프레드 헛친슨 켄서 리서치 센터 Ras 신항원에 특이적인 결합 단백질 및 이의 용도
US20220175899A1 (en) * 2019-04-11 2022-06-09 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer
CN110172089B (zh) * 2019-06-11 2020-01-07 北京鼎成肽源生物技术有限公司 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用
CN112110995A (zh) * 2019-06-19 2020-12-22 上海交通大学医学院 肿瘤新抗原多肽及其用途
US20210342750A1 (en) * 2019-08-14 2021-11-04 Nec Corporation Information processing apparatus, information processing method, and storage medium
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术（广东）有限公司 一种识别Kras G12V的高亲和力TCR
CN115244173A (zh) 2019-12-20 2022-10-25 英研生物(英国)有限公司 用于分离肿瘤浸润淋巴细胞的装置及方法及其用途
KR20220143875A (ko) * 2020-02-14 2022-10-25 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 G12v 돌연변이를 갖는 ras에 대한 hla 클래스 i-제한된 t 세포 수용체
CN111574616B (zh) * 2020-06-17 2021-02-02 深圳豪石生物科技有限公司 分离的t细胞受体和应用
EP4182029B1 (en) * 2020-07-16 2025-12-31 The United States of America, as represented by the Secretary, Department of Health and Human Services HLA-restricted class II DRB T lymphocyte receptors directed against RAS, including a G12V mutation
US20230365649A1 (en) * 2020-10-02 2023-11-16 The Usa, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted dq t cell receptors against ras with g13d mutation
CA3209732A1 (en) 2021-02-25 2022-09-01 Drew Caldwell DENIGER Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells
CN114920824B (zh) * 2022-05-27 2023-12-05 重庆医科大学 Tcr或其抗原结合片段及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301017B2 (en) * 2002-05-30 2007-11-27 Kolesnick Richard N Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
DK1545204T3 (en) 2002-09-06 2016-11-14 The Government Of The Us Secretary Dept Of Health And Human Services Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy
EP3369812B1 (en) * 2005-08-05 2020-10-07 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Generation of antigen specific t cells
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
CA3071740C (en) 2010-09-20 2020-09-08 Biontech Ag Antigen-specific t cell receptors and t cell epitopes
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
EP3766896B1 (en) 2011-09-15 2025-11-05 The United States of America, as represented by The Secretary, Department of Health and Human Services T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
GB201314404D0 (en) * 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
JP6863893B2 (ja) 2014-11-26 2021-04-21 アメリカ合衆国 抗突然変異ｋｒａｓ ｔ細胞受容体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FREDERICK D. TSAI ET AL,, K-RAS4A SPLICE VARIANT IS WIDELY EXPRESSED IN CANCER AND USES A HYBRID MEMBRANE-TARGETING MOTIF, 5 January 2015 (2015-01-05) *

Also Published As

Publication number Publication date
HK1257902A1 (en) 2019-11-01
US10556940B2 (en) 2020-02-11
AU2022209229B2 (en) 2024-05-23
CN108350059A (zh) 2018-07-31
KR20250117744A (ko) 2025-08-05
CA2998869A1 (en) 2017-03-23
SG10201913868XA (en) 2020-03-30
CN115073583A (zh) 2022-09-20
JP7185524B2 (ja) 2022-12-07
US20200148739A1 (en) 2020-05-14
EP3350213A1 (en) 2018-07-25
KR102841067B1 (ko) 2025-08-01
AU2016323017B2 (en) 2020-11-12
US11667692B2 (en) 2023-06-06
CN108350059B (zh) 2021-10-08
AU2021200833B2 (en) 2022-04-28
WO2017048593A1 (en) 2017-03-23
ES2879287T3 (es) 2021-11-22
IL257840A (en) 2018-04-30
MX2018003062A (es) 2018-09-11
US20190040111A1 (en) 2019-02-07
US20230406904A1 (en) 2023-12-21
JP7461445B2 (ja) 2024-04-03
EP3350213B1 (en) 2021-03-31
JP2018535647A (ja) 2018-12-06
AU2016323017A1 (en) 2018-04-05
DK3350213T3 (da) 2021-06-21
AU2022209229A1 (en) 2022-09-15
AU2021200833A1 (en) 2021-03-04
IL257840B1 (en) 2023-06-01
KR20180044428A (ko) 2018-05-02
EP3901169A1 (en) 2021-10-27
SA518391109B1 (ar) 2022-02-14
JP2023025108A (ja) 2023-02-21

Similar Documents

Publication Publication Date Title
US20230406904A1 (en) T cell receptors recognizing hla-cw8 restricted mutated kras
US11840561B2 (en) Anti-KRAS-G12D T cell receptors
US11352410B2 (en) Anti-KK-LC-1 T cell receptors
JP7635165B2 (ja) ｐ５３におけるＲ１７５Ｈ又はＹ２２０Ｃ変異を認識するＴ細胞受容体
CA2998869C (en) T cell receptors recognizing hla-cw8 restricted mutated kras
HK1257902B (en) T cell receptors recognizing hla-cw8 restricted mutated kras
WO2022225836A1 (en) Hla class i-restricted t cell receptors against ras with q61k mutation